Brain amyloid contribution to cognitive dysfunction in Lewy bodies disorders: a pilot study
Objective: To investigate regional [18F]florbetapir binding to amyloid-β and its contribution to cognitive dysfunction in Lewy bodies disorders. Background: Lewy bodies disorders like Parkinson’s disease…Molecular correlates of survival and clinical severity in Progressive Supranuclear Palsy
Objective: To test how regional tau pathology and neuroinflammation are associated with clinical severity and survival in progressive supranuclear palsy (PSP). Background: The abnormal aggregation…Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Parkinson’s Disease: An in vivo [11C]BU99008 PET study
Objective: We aimed to evaluate the role of astroglia activation in Parkinson's disease (PD) using [11C]BU99008 PET, a novel radioligand with high specificity and selectivity…Visual hallucinations in Parkinson´s disease and amyloid burden: 18F-Flutemetamol PET-MRI study
Objective: To compare amyloid distribution in patients with Parkinson´s disease (PD) with visual hallucinations (VH-p) and without (VH-n). Background: In patients with PD the prevalence…Is 18F-FDG-PET/CT a helpful tool to diagnose PSP clinical variants?
Objective: To assess if there are differential metabolic brain patterns among Progressive Supranuclear Palsy(PSP) clinical variants and between them and Parkinson’s disease patients (PD). Background:…Evaluation of Imidazoline 2 binding sites reflecting astroglia pathology in Huntington’s Disease: An in vivo [11C]BU99008 PET study
Objective: We aimed to evaluate the role of astroglia activation in Huntington’s disease gene expansion carriers (HDGECs) using [11C]BU99008 PET, a novel radioligand with high specificity and…Functional connectivity and microstructural alterations in regions of synaptic density loss in DLB and PDD
Objective: We aimed to investigate whether functional connectivity and white matter integrity is altered in regions exhibiting reduced synaptic density, as measured by [11C]UCB-J-PET,in Dementia with…11C-PBB3 PET in PD: does alpha-synuclein pathology start in axonal terminals?
Objective: To use 11C-PBB3 PET binding to monitor alpha-synuclein (a-syn) pathology in PD subjects in vivo. Background: In previous work we have shown binding of…The role of Synaptic vesicle protein 2A (SV2A) in patients with Parkinson’s disease dementia and Dementia with Lewy bodies: An in vivo [11C]UCB-J PET study
Objective: We aimed to investigate the role of synaptic vesicle glycoprotein 2A (SV2A) in Parkinson’s disease dementia (PDD) and Dementia with Lewy bodies (DLB) using…Multimodal PET and fcMRI reveals regional modulation by STN DBS correlating to motor outcomes
Objective: To define brain networks modulated by deep brain stimulation (DBS) of the subthalamic nucleus (STN) and correlate connectivity with motor outcomes. Background: STN DBS…
- « Previous Page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- …
- 35
- Next Page »